Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

08 September 2020 : Original article  

Prediction of Liver Prognosis from Pre-Transplant Renal Function Adjusted by Diuretics and Urinary Abnormalities in Adult-to-Adult Living Donor Liver Transplantation

Mineaki Kitamura1ABCDEFG*, Masaaki Hidaka2ABDE, Kumiko Muta1BC, Satoshi Miuma3BDE, Hisamitsu Miyaaki3CD, Mitsuhisa Takatsuki2D, Kazuhiko Nakao3D, Susumu Eguchi2DE, Hiroshi Mukae4D, Tomoya Nishino1ACDE

DOI: 10.12659/AOT.924805

Ann Transplant 2020; 25:e924805

Table 1 Demographic data of liver transplantation recipients according to graft survival.

Total (N=244)Survived (N=156)Graft loss (N=88)P value
Observational period (days)1689 (533–3346)2451 (1328–4063)286 (42–1225)
Recipient age (years)54.4 (10.8)53.2 (11.9)56.6 (8.3)0.07
Recipient sex, Male (%)57.8%55.1%62.5%0.26
Recipient height (cm)162 (9.4)162 (9.5)161 (9.3)0.44
Recipient weight (kg)63.3 (13.1)64.0 (13.8)62.0 (12.0)0.35
Donor age (years)39.9 (12.8)37.4 (12.5)44.4 (12.2)<0.001
Donor sex, Male (%)57.3%59.0%54.5%0.50
MELD score18.6 (8.3)17.9 (7.7)19.9 (9.4)0.18
Cirrhosis due to hepatitis B virus (%)16.0%17.3%13.6%0.45
Cirrhosis due to hepatitis C virus (%)38.1%34.0%45.5%0.08
Cirrhosis due to alcohol (%)14.8%16.0%12.5%0.45
Hepatocellular carcinoma41.8%40.3%44.3%0.55
Diabetes25.0%21.1%31.8%0.06
Hypertension18.9%14.1%27.2%0.01
Chronic kidney disease23.7%18.8%32.2%0.02
Ascites (+)53.2%50.0%59.1%0.17
Type 1 Hepatorenal syndrome2.0%0.6%4.6%0.04
Type 2 Hepatorenal syndrome6.6%3.8%11.3%0.02
Use of diuretics63.9%64.7%62.5%0.73
Loop diuretics57.8%59.6%54.5%0.44
Anti-aldosterone diuretics51.6%54.5%46.6%0.24
Tolvaptan11.0%10.9%11.3%0.91
Thiazide5.4%5.8%1.1%0.08
Hemoglobin (g/dL)10.4 (2.2)10.5 (2.3)10.3 (2.2)0.55
Platelets (×10) (/μL)80.8 (56.3)77.2 (53.9)87.1 (60.1)0.13
Prothrombin time (%)52.1 (18.6)51.4 (17.6)53.2 (20.2)0.59
Total bilirubin (mg/dL)7.7 (9.3)7.4 (9.3)8.2 (9.4)0.92
Aspartate aminotransferase (IU/L)100 (151)95 (159)108 (135)0.42
Alanine aminotransferase (IU/L)90 (184)87 (187)94 (179)0.82
Albumin (g/dL)2.94 (0.58)2.89 (0.58)3.04 (0.58)0.046
Creatinine (mg/dL)1.11 (1.21)0.89 (0.62)1.52 (1.78)<0.001
eGFR(mL/min/1.73 m)72.6 (33.3)77.4 (31.6)64.0 (34.7)0.01
Urinary abnormalities24.9%21.5%31.1%0.11
Proteinuria >1+9.5%6.3%15.6%0.02
Hematuria >1+21.0%18.2%26.3%0.17
Intra-operative hemorrhage (mL)9801 (11674)8620 (7953)11894 (16157)0.35
Graft volume/standard liver volume (%)48.6 (12.6)49.4 (13.4)47.3 (11.1)0.50
Calcineurin inhibitors (%)79.7%91.7%57.6%<0.001
Mycophenolate mofetil (%)54.8%61.5%42.3%0.11
Data are represented as medians (interquartile ranges), percentages (%), or means (standard deviations) and collected pre- or at transplantation. MELD – model for end-stage liver disease.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358